Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-AML2024 venetoclax-based therapy in pediatric AML (non-APL)
ChiCTR2400080307Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Overall survival (OS), Event-free survival (EFS) and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400080307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080307.